BIG NEWS!!!; THE DATA IS FINALLY HERE!!!:
The (drug?)(TM) study was a randomized, double-blind, placebo-controlled trial conducted in 33 U.S. medical centers that evaluated two (?)(TM) doses in 240 patients with severe sepsis or severe traumatic injuries at risk for the development of ARDS (acute respiratory distress syndrome).
Both dose groups showed quantifiable differences. The results that follow represent one of the (drug?)(TM) dose groups as compared to placebo.
Treatment with (?)(TM) in patients that were at risk for the development of ARDS resulted in a STATISTICALLY SIGNIFICANT reduction of death compared to placebo: for 28-day all cause mortality, the death rate with (?)(TM) was 14.5% vs. 28.4% for placebo (p less than or equal to 0.034).
This decreased mortality was accompanied by a STATISTICALLY SIGNIFICANT reduction in the incidence of ARDS (ARDS:23.8% for (?)(TM) vs. 37.0% for placebo, p less than or equal to 0.049) and a trend toward a reduction in median length of stay in the intensive care unit (10 days for (?)(TM) vs. 16 days for placebo).
The results for the two patient populations can be reported separately for the same dose group.
In patients with severe sepsis, the reduction in 28-day all cause mortality was STATISTICALLY SIGNIFICANT with a death rate of 21.4% with (?)(TM) vs. 44.2% with placebo (p less than or equal to 0.026),
...the incidence of ARDS was 35.6% with (?)(TM) vs. 48.8% with placebo, and the median length of stay in the intensive care unit was 11 days with (?)TM) vs. 20 days with placebo.
In patients with severe traumatic injuries, 28-day all cause mortality was 5.9% with (?)(TM) vs. 10.5% with placebo,
....the incidence of ARDS was 8.6% with (?)(TM) vs. 23.7% with placebo, and the median length of stay in the intensive care unit was 8.0 days with (?)(TM) vs. 15.5 days with placebo.
Administration of (?)TM) to patients with severe sepsis or severe traumatic injuries was SAFE and well tolerated.
No serious treatment-related adverse events attributable to (?)(TM) were reported in the study.
"This study is THE ONLY ONE to demonstrate a decrease in the incidence of ARDS in severely injured trauma (HUMANS !!!)patients as well as a significant decrease in mortality in septic patients,"
CAVEAT: Replace (?) with PAFASE, not rbpi and the company is NOT xoma, IT IS ICOS!!!
Where my money is!!!
Good luck with the rest of the technology. |
